Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis

被引:5
|
作者
Poznyak, Anastasia V. [1 ]
Sukhorukov, Vasily N. [2 ]
Eremin, Ilya I. [3 ]
Nadelyaeva, Irina I. [3 ]
Gutyrchik, Nikita A. [3 ]
Orekhov, Alexander N. [2 ]
机构
[1] Inst Atherosclerosis Res, Osennyaya 4-1-207, Moscow 121609, Russia
[2] Russian Acad Med Sci, Inst Gen Pathol & Pathophysiol, Moscow 125315, Russia
[3] Petrovsky Natl Res Ctr Surg, 2 Abrikosovsky Lane, Moscow 119991, Russia
基金
俄罗斯科学基金会;
关键词
PCSK9; atherosclerosis; cardiovascular disease; CVD; lipids; lipid metabolism; LDL RECEPTORS; CARDIOVASCULAR EVENTS; PCSK9; INHIBITION; POOLED ANALYSIS; SAFETY; CHOLESTEROL; EVOLOCUMAB; EFFICACY; DEGRADATION; ALIROCUMAB;
D O I
10.3390/biomedicines11020503
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite being the most common treatment strategy in the management of atherosclerosis and subsequent cardiovascular disease, classical statin therapy has certain disadvantages, including numerous side effects. In addition, a regimen with daily administration of the drug is hard to comply with. Thus, there is a need for modern and more efficient therapeutic strategies in CVD treatment. There is extensive evidence indicating that PCSK9 promotes atherogenesis through a variety of mechanisms. Thus, new treatment methods can be developed that prevent or alleviate atherosclerotic cardiovascular disease by targeting PCSK9. Comprehensive understanding of its atherogenic properties is a necessary precondition for the establishment of new therapeutic strategies. In this review, we will summarize the available data on the role of PCSK9 in the development and progression of atherosclerosis. In the last section, we will consider existing PCSK9 inhibitors.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Proprotein convertase subtilisin/kexin type 9 and lipid metabolism
    Spolitu, Stefano
    Dai, Wen
    Zadroga, John A.
    Ozcan, Lale
    CURRENT OPINION IN LIPIDOLOGY, 2019, 30 (03) : 186 - 191
  • [2] The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function
    Amput, Patchareeya
    McSweeney, Christian
    Palee, Siripong
    Phrommintikul, Arintaya
    Chattipakorn, Siriporn C.
    Chattipakorn, Nipon
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 109 : 1171 - 1180
  • [3] Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke
    Zhang, Lingling
    Song, Kangping
    Zhu, Mengting
    Shi, Jinling
    Zhang, Huijuan
    Xu, Liang
    Chen, Yingzhu
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2016, 126 (08) : 675 - 680
  • [4] Proprotein Convertase subtilisin Kexin 9 Inhibitors
    Pirillo, Angela
    Catapano, Alberico Luigi
    CARDIOLOGY CLINICS, 2018, 36 (02) : 241 - +
  • [5] Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism
    Guo, Shoudong
    Xia, Xiao-dan
    Gu, Hong-mei
    Zhang, Da-wei
    LIPID TRANSFER IN LIPOPROTEIN METABOLISM AND CARDIOVASCULAR DISEASE, 2020, 1276 : 137 - 156
  • [6] PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review
    Dua, Pamila
    Reeta, K. H.
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2020, 6 (03) : 226 - 233
  • [7] A short review of proprotein convertase subtilisin/kexin type 9 inhibitors
    Alali, Rudaynah A.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2019, 20 (01) : 1 - 8
  • [8] Proprotein convertase subtilisin/kexin type 9 inhibition
    Marais, David A.
    Blom, Dirk J.
    Petrides, Francine
    Goueffic, Yann
    Lambert, Gilles
    CURRENT OPINION IN LIPIDOLOGY, 2012, 23 (06) : 511 - 517
  • [9] Proprotein convertase subtilisin/kexin type 9 in kidney disease
    Schmit, David
    Fliser, Danilo
    Speer, Thimoteus
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (08) : 1266 - 1271
  • [10] Proprotein Convertase Subtilisin/Kexin 6 Is Involved In Lipid Metabolism In Liver
    Suur, Bianca
    Chemaly, Melody
    Karadimou, Glykeria
    Jin, Hong
    Kronqvist, Malin
    Lengquist, Mariette
    van der Laan, Sander W.
    Lleal, Maria Sabater
    Malarstig, Anders
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2022, 42